One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy

J. G. Teeter, the Exubera® Phase III Study Group (Groton, United States Of America)

Source: Annual Congress 2004 - Cystic fibrosis: the expanding clinical issues
Session: Cystic fibrosis: the expanding clinical issues
Session type: Thematic Poster Session
Number: 3773
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. G. Teeter, the Exubera® Phase III Study Group (Groton, United States Of America). One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy. Eur Respir J 2004; 24: Suppl. 48, 3773

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of oral add-on therapy in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009

Effect of discontinuation and readministration of inhaled human insulin on pulmonary safety in adult diabetes patients
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology
Year: 2007


Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006

Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020
Year: 2021



The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma
Source: Annual Congress 2010 - Allergy and risk factors in paediatrics
Year: 2010


First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Safety profile of tiotropium add-on therapy in paediatric patients by gender
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019

Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008


Comparative clinical-functional effectiveness and cardiological safety of short-acting combined broncholytics in 2 months basic therapy in COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 74s
Year: 2007

Long-term use of inhaled corticosteroids and the risk of type 2 diabetes in COPD
Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases
Year: 2020

Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012